FEATURED ARTICLE

 

MeiraGTx Receives Rare Pediatric Disease Designation for A001 for the Treatment of Leber's Congenital Amaurosis and Treats First Pediatric Patient in Phase 1/2 Clinical Trial

PR Newswire  2017-12-07 13:30:00

LONDON and NEW YORK, Dec. 7, 2017 /PRNewswire/ -- MeiraGTx, a London and New York-based gene therapy company, today announced that the Offices of Orphan Products Development and Pediatric Therapeutics of the U.S. Food and Drug Administration (FDA) have granted rare pediatric disease...

Full Story »

Comments

No Comments
Your name: *
Email:
Comment: *
 
Share
submit to reddit
Expedia